COSCIENS Biopharma Says 'Although Further Analysis of the Study Results Is Required, Initial Review of the Results Indicates That the Comparator Tests May Have Led to a High False Positive Rate Which Impacted Macimorelin's Ability to Reach the Primary...

COSCIENS生物製藥表示：“雖然對研究結果的進一步分析尚需進行，但初步結果的初步審查表明比較試驗可能導致了較高的假陽性率，這影響了馬西瑞林達到首要目標...

Benzinga · 08/27 19:33

COSCIENS Biopharma Says 'Although Further Analysis of the Study Results Is Required, Initial Review of the Results Indicates That the Comparator Tests May Have Led to a High False Positive Rate Which Impacted Macimorelin's Ability to Reach the Primary Efficacy Endpoint.'

COSCIENS Biopharma表示：「儘管需要進一步對研究結果進行分析，但初步審查結果表明，比較試驗可能導致高假陰性率，影響了Macimorelin達到主要療效終點的能力。」

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。